Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide 50 mg Effect on Energy Intake in Obesity
NCT05236517Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Semaglutide 50 mg with Placebo (2 arms). Primary endpoint: Relative change in energy intake during ad libitum lunch at Day 140. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05236517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236517.